16 Sep, 2019 RNAi Roundtable: Patisiran & Vutrisiran, in Development for the Treatment of Transthyretin-Mediated Amyloidosis
Posted at 15:19h
in Capella
On September 16, 2019, we hosted an online RNAi Roundtable to review the progress with patisiran and vutrisiran, RNAi therapeutics in development for the treatment of transthyretin-mediated amyloidosis.
ONPATTRO® (patisiran) is approved in the U.S. and Canada for the treatment of the polyneuropathy of hATTR amyloidosis in adults, in the EU for the treatment of hATTR amyloidosis in adults with stage 1 or stage 2 polyneuropathy, and in Japan for the treatment of transthyretin (TTR) type familial amyloidosis with polyneuropathy. Vutrisiran is an investigational RNAi therapeutic in development for the treatment of ATTR amyloidosis.
-
- Eric Green, Senior Vice President, General Manager, TTR Program
- Mike, Patient Diagnosed with hATTR Amyloidosis
- John Vest, M.D., Executive Director, Clinical Research
- Rena Denoncourt, Senior Director, Program Leader, Vutrisiran Program
